{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T16:31:23Z","timestamp":1770222683708,"version":"3.49.0"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"14","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Soluble mesothelin-related peptide (SMRP) is a widely studied tumor marker for diagnosing malignant pleural mesothelioma (MPM). This study discussed the diagnostic value of SMRPs in pleural effusion (PE) for MPM.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Medline, Embase, Web of Science, and Cochrane library system were systematically searched on the data of SMRPs in PE for MPM diagnosis. Pooled diagnostic sensitivity, specificity, and symmetric receiver operating characteristic curve were calculated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Thirteen studies fulfilled the inclusion criteria and a total of 3359 cases including 759 MPM cases, 1061 non-MM (malignant mesothelioma) malignant PE, and 1539 benign PE were brought into this meta-analysis. The pooled results of SMRPs in PE for diagnosing MPM were as follows: sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio were 0.68 (95% confidence interval [CI]: 0.64\u20130.72), 0.91 (95% CI: 0.86\u20130.94), 7.8 (95% CI: 5.0\u201312.0), 0.35 (95% CI: 0.31\u20130.40), and 22 (95% CI: 14\u201335), respectively. The area under the summary receiver operating characteristic curves (AUC) was 0.75 (95% CI: 0.72\u20130.80). Subgroup analyzes revealed that the AUC of cohort group using histological diagnosis could be improved to 0.86 (95% CI: 0.83, 0.89). The Deek's funnel plot asymmetry test showed no publication bias.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Although the sensitivity of SMRPs was low, PE-SMRPs can be a good indicator of the existence of MPM.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000014979","type":"journal-article","created":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T18:24:45Z","timestamp":1554488685000},"page":"e14979","source":"Crossref","is-referenced-by-count":17,"title":["Diagnostic value of soluble mesothelin-related peptides in pleural effusion for malignant pleural mesothelioma"],"prefix":"10.1097","volume":"98","author":[{"given":"Ruiyue","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanbing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huanzhong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaohui","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230914","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jtho.2018.02.021","article-title":"Progress in the management of malignant pleural mesothelioma in 2017","volume":"13","author":"McCambridge","year":"2018","journal-title":"J Thorac Oncol"},{"key":"R2-20230914","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S1470-2045(13)70257-2","article-title":"Asbestos is not just asbestos: an unrecognised health hazard","volume":"14","author":"Baumann","year":"2013","journal-title":"Lancet Oncol"},{"key":"R3-20230914","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jtho.2016.12.006","article-title":"Improving the accuracy of mesothelioma diagnosis in China","volume":"12","author":"Guo","year":"2017","journal-title":"J Thorac Oncol"},{"key":"R4-20230914","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/resp.12517","article-title":"Asbestos in Asia","volume":"20","author":"Leong","year":"2015","journal-title":"Respirology"},{"key":"R5-20230914","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1136\/oemed-2017-104298","article-title":"Estimation of the global burden of mesothelioma deaths from incomplete national mortality data","volume":"74","author":"Odgerel","year":"2017","journal-title":"Occup Environ Med"},{"key":"R7-20230914","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmjopen-2013-004145","article-title":"Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis","volume":"4","author":"Cui","year":"2014","journal-title":"BMJ Open"},{"key":"R8-20230914","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.cca.2014.02.024","article-title":"Diagnostic accuracy of osteopontin for malignant pleural mesothelioma: a systematic review and meta-analysis","volume":"433","author":"Hu Z. De","year":"2014","journal-title":"Clin Chim Acta"},{"key":"R9-20230914","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1115050","article-title":"Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma","volume":"367","author":"Pass","year":"2012","journal-title":"N Engl J Med"},{"key":"R10-20230914","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1158\/1078-0432.CCR-15-1130","article-title":"HMGB1 and its hyperacetylated isoform are sensitive and specific serum biomarkers to detect asbestos exposure and to identify mesothelioma patients","volume":"22","author":"Napolitano","year":"2016","journal-title":"Clin Cancer Res"},{"key":"R11-20230914","doi-asserted-by":"crossref","first-page":"9190","DOI":"10.1074\/jbc.M312372200","article-title":"Binding of ovarian cancer antigen CA125\/MUC16 to mesothelin mediates cell adhesion","volume":"279","author":"Rump","year":"2004","journal-title":"J Biol Chem"},{"key":"R12-20230914","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1073\/pnas.93.1.136","article-title":"Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers","volume":"93","author":"Chang","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R13-20230914","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/j.1349-7006.2007.00715.x","article-title":"Aberrant splicing and protease involvement in mesothelin release from epithelioid mesothelioma cells","volume":"99","author":"Sapede","year":"2008","journal-title":"Cancer Sci"},{"key":"R14-20230914","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1515\/CCLM.2011.242","article-title":"Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma","volume":"49","author":"Yamada","year":"2011","journal-title":"Clin Chem Lab Med"},{"key":"R15-20230914","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.rmed.2009.05.017","article-title":"Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a meta-analysis","volume":"104","author":"Luo","year":"2010","journal-title":"Respir Med"},{"key":"R16-20230914","doi-asserted-by":"crossref","first-page":"413946","DOI":"10.1155\/2014\/413946","article-title":"Pleural fluid mesothelin as an adjunct to the diagnosis of pleural malignant mesothelioma","volume":"2014","author":"Creaney","year":"2014","journal-title":"Dis Markers"},{"key":"R17-20230914","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1164\/rccm.200511-1789OC","article-title":"Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma","volume":"173","author":"Scherpereel","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"R18-20230914","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/JTO.0b013e31824c9272","article-title":"CCL2, galectin-3, and SMRP combination improves the diagnosis of mesothelioma in pleural effusions","volume":"7","author":"Blanquart","year":"2012","journal-title":"J Thorac Oncol"},{"key":"R19-20230914","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s12032-013-0649-x","article-title":"Clinical value of mesothelin in pleural effusions versus histology by medical thoracoscopy: brief report","volume":"30","author":"Canessa","year":"2013","journal-title":"Med Oncol"},{"key":"R20-20230914","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3109\/07357907.2012.749265","article-title":"Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology","volume":"31","author":"Canessa","year":"2013","journal-title":"Cancer Invest"},{"key":"R21-20230914","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/thoraxjnl-2014-205205","article-title":"Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma","volume":"69","author":"Creaney","year":"2014","journal-title":"Thorax"},{"key":"R22-20230914","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1164\/rccm.200811-1729OC","article-title":"Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions","volume":"180","author":"Davies","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"R23-20230914","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s12032-013-0543-6","article-title":"Diagnostic value of mesothelin in pleural fluids: comparison with CYFRA 21-1 and CEA","volume":"30","author":"Filiberti","year":"2013","journal-title":"Med Oncol"},{"key":"R24-20230914","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3892\/etm_00000048","article-title":"Soluble mesothelin-related protein in pleural effusion from patients with malignant pleural mesothelioma","volume":"1","author":"Fujimoto","year":"2010","journal-title":"Exp Ther Med"},{"key":"R25-20230914","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1183\/09031936.00148211","article-title":"A prospective trial evaluating the role of mesothelin in undiagnosed pleural effusions","volume":"41","author":"Hooper","year":"2013","journal-title":"Eur Respir J"},{"key":"R26-20230914","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.athoracsur.2007.07.042","article-title":"Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions","volume":"85","author":"Pass","year":"2008","journal-title":"Ann Thorac Surg"},{"key":"R27-20230914","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1136\/thx.2006.068114","article-title":"Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma","volume":"62","author":"Creaney","year":"2007","journal-title":"Thorax"},{"key":"R28-20230914","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0185850","article-title":"Pleural effusion biomarkers and computed tomography findings in diagnosing malignant pleural mesothelioma: a retrospective study in a single center","volume":"12","author":"Otoshi","year":"2017","journal-title":"PLoS One"},{"key":"R29-20230914","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1373\/clinchem.2007.096032","article-title":"Bias in sensitivity and specificity caused by data-driven selection of optimal cutoff values: mechanisms magnitude, and solutions","volume":"54","author":"Leeflang","year":"2008","journal-title":"Clin Chem"},{"key":"R30-20230914","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1159\/000468545","article-title":"Diagnostic accuracy of combinations of tumor markers for malignant pleural effusion: an updated meta-analysis","volume":"94","author":"Yang","year":"2017","journal-title":"Respiration"},{"key":"R31-20230914","doi-asserted-by":"crossref","first-page":"5220","DOI":"10.21037\/jtd.2017.11.62","article-title":"Diagnostic accuracy of tumor markers for malignant pleural effusion: a derivation and validation study","volume":"9","author":"Zhai","year":"2017","journal-title":"J Thorac Dis"},{"key":"R32-20230914","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.lungcan.2011.01.011","article-title":"Mesothelin and kidney function\u2014analysis of relationship and implications for mesothelioma screening","volume":"73","author":"Boudville","year":"2011","journal-title":"Lung Cancer"},{"key":"R33-20230914","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1001\/jama.1994.03510290071040","article-title":"Users\u2019 guides to the medical literature. III. How to use an article about a diagnostic test. A. Are the results of the study valid? Evidence-Based Medicine Working Group","volume":"271","author":"Jaeschke","year":"1994","journal-title":"JAMA"},{"key":"R34-20230914","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1471-2288-3-25","article-title":"The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews","volume":"3","author":"Whiting","year":"2003","journal-title":"BMC Med Res Methodol"},{"key":"R35-20230914","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1471-2288-11-27","article-title":"Uptake of newer methodological developments and the deployment of meta-analysis in diagnostic test research: a systematic review","volume":"11","author":"Willis","year":"2011","journal-title":"BMC Med Res Methodol"},{"key":"R36-20230914","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"Research and reporting methods accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Intern Med"},{"key":"R37-20230914","doi-asserted-by":"crossref","first-page":"S353","DOI":"10.21037\/jtd.2017.10.132","article-title":"Serum mesothelin and other biomarkers: what have we learned in the last decade?","volume":"10","author":"Cristaudo","year":"2018","journal-title":"J Thorac Dis"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201904050-00016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T20:47:03Z","timestamp":1694724423000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201904050-00016"}},"subtitle":["An updated meta-analysis"],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":36,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000014979","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4]]}}}